Why choose the Oncotype DX Breast Recurrence Score Test?
Why choose the Oncotype DX Breast Recurrence Score Test?The Oncotype DX Breast Recurrence Score test identifies the vast majority of women who may not benefit from the addition of chemotherapy to endocrine therapy and the important minority of women for whom chemotherapy may be life-saving.2,4,9
- The only assay proven to predict chemotherapy benefit2
- Independent predictor of chemotherapy benefit and patient outcomes2
- Can help reduce over- and undertreatment4,14-18
- Can help guide treatment decisions across age groups4
- Consistent and large body of evidence across prospective randomised trials, validation studies and real-world evidence1-10
The Oncotype DX® test as standard of care to guide chemotherapy treatment decisionsDue to the comprehensive dataset of the Oncotype DX Breast Recurrence Score test, guidelines and HTA body recommendations position the Oncotype DX test as the preferred multigene assay.1-8
All recommendations have been updated after the publication of the two major clinical trials TAILORx and RxPONDER.
The trials looked at different patient populations, node-negative and node-positive respectively. As a result, some recommendations are classified by nodal status to reflect the wealth of data available.
Below is a high-level overview of each of the major guidelines and HTA bodies worldwide.
Inclusion in Major Guidelines and Health Technology Assessment bodies
For further information, please click https://www.oncotypedxtest.com/